Zobrazeno 1 - 10
of 30
pro vyhledávání: '"María Luisa Martínez‐Ginés"'
Autor:
María Inmaculada Domínguez-Mozo, Inés González-Suárez, Luisa María Villar, Lucienne Costa-Frossard, Noelia Villarrubia, Yolanda Aladro, Belén Pilo, Xavier Montalbán, Manuel Comabella, Ignacio Casanova-Peño, María Luisa Martínez-Ginés, Jose Manuel García-Domínguez, María Ángel García-Martínez, Rafael Arroyo, Roberto Álvarez-Lafuente
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
BackgroundEpstein–Barr virus (EBV) and human herpesvirus 6 (HHV-6) have been associated with multiple sclerosis (MS). Teriflunomide is an oral disease-modifying therapy approved for treatment of relapsing forms of MS. In the preclinical Theiler’s
Externí odkaz:
https://doaj.org/article/932dbd9284cf433081432ebfa5ee9061
Autor:
Francisco Carlos Pérez‐Miralles, Daniel Prefasi, Antonio García‐Merino, José Ramón Ara, Guillermo Izquierdo, Virginia Meca‐Lallana, Francisco Gascón‐Giménez, María Luisa Martínez‐Ginés, Lluis Ramió‐Torrentà, Lucienne Costa‐Frossard, Óscar Fernández, Sara Moreno‐García, Jorge Maurino, Joan Carreres‐Polo, Bonaventura Casanova
Publikováno v:
Brain and Behavior, Vol 11, Iss 4, Pp n/a-n/a (2021)
Abstract Background and purpose Evidence on regional changes resulting from neurodegenerative processes underlying primary progressive multiple sclerosis (PPMS) is still limited. We assessed brain region volumes and their relationship with disability
Externí odkaz:
https://doaj.org/article/1c68c742d928479ab6b1cd9c261aafe7
Autor:
Francisco Barrero, Javier Mallada-Frechin, María Luisa Martínez-Ginés, María Eugenia Marzo, Virginia Meca-Lallana, Guillermo Izquierdo, José Ramón Ara, Celia Oreja-Guevara, José Meca-Lallana, Lucía Forero, Irene Sánchez-Vera, María José Moreno, in representation of the MS NEXT study investigators
Publikováno v:
PLoS ONE, Vol 15, Iss 4, p e0230846 (2020)
PurposeThe objective of this study was to characterize the demographic and clinical profile of RRMS patients receiving fingolimod in Spain, and to evaluate drug effectiveness and safety in clinical practice.MethodsThis observational, retrospective, m
Externí odkaz:
https://doaj.org/article/35e01650c3644a1095a86b39b5d34dd7
Autor:
María Cristina Ortega, Rafael Lebrón-Galán, Isabel Machín-Díaz, Michelle Naughton, Inmaculada Pérez-Molina, Jennifer García-Arocha, Jose Manuel Garcia-Dominguez, Haydee Goicoechea-Briceño, Virginia Vila-del Sol, Víctor Quintanero-Casero, Rosa García-Montero, Victoria Galán, Leticia Calahorra, Celia Camacho-Toledano, María Luisa Martínez-Ginés, Denise C. Fitzgerald, Diego Clemente
Publikováno v:
Acta Neuropathologica.
Multiple sclerosis (MS) is a highly heterogeneous demyelinating disease of the central nervous system (CNS) that needs for reliable biomarkers to foresee disease severity. Recently, myeloid-derived suppressor cells (MDSCs) have emerged as an immune c
Autor:
Haydee Goicochea Briceño, Yolanda Higueras, José Manuel García Domínguez, Ariana Meldaña Rivera, Juan Pablo Cuello, Elda Alba Suárez, María Luisa Martínez Ginés
Publikováno v:
Revista Científica de la Sociedad Española de Enfermería Neurológica.
Autor:
Estefania Garcia-Calvo, María Luisa Martínez Ginés, Silvia Medina Heras, José Ignacio Fernández Velasco, Hector Estevez, Haydee Goicochea Briceño, Juan De León-Luis, José Manuel García Domínguez, Ariana Meldaña Rivera, Silvia Pérez-Pérez, Juan Pablo Cuello, Roberto Alvarez-Lafuente, Amalia Tejeda-Velarde, María Ángel García-Martínez, Yolanda Higueras, Jose L. Luque-Garcia, Alberto Lozano Ros, Luisa M. Villar, Santiago Garcia-Tizon, Beatriz Pardo-Rodríguez, Maria Inmaculada Dominguez-Mozo
Publikováno v:
European Journal of Neurology. 29:895-900
Short-chain fatty acids (SCFAs) can have pro- or anti-inflammatory properties, but their relationship with multiple sclerosis (MS) relapses during pregnancy remains unknown. This study aimed to explore SCFA profiles in MS patients during pregnancy an
Autor:
María Cristina Ortega, Rafael Lebrón-Galán, Isabel Machín-Díaz, Michelle Naughton, Inmaculada Pérez-Molina, Jennifer García-Arocha, Jose Manuel García-Domínguez, Haydee Goicoechea-Briceño, Virginia Vila-del Sol, Víctor Quintanero-Casero, Rosa García-Montero, Victoria Galán, Celia Camacho-Toledano, María Luisa Martínez-Ginés, Denise C. Fitzgerald, Diego Clemente
Multiple Sclerosis (MS) is a highly heterogeneous demyelinating disease of the central nervous system (CNS) that needs for reliable biomarkers to foresee disease severity. Previous retrospective investigations in the MS model, experimental autoimmune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::040ee458034413355ee9074578842bf5
https://doi.org/10.1101/2022.04.20.488896
https://doi.org/10.1101/2022.04.20.488896
Autor:
Luis Brieva, Bonaventura Casanova Estruch, Juan Antonio García Merino, Virginia Meca-Lallana, Jordi Río, Alfredo Rodríguez-Antigüedad, Eduardo Agüera, Jose Ramón Ara, Adrián Arés Luque, Carmen Arnal Garcia, Yolanda Blanco, Tamara Castillo-Triviño, Lucienne Costa-Frossard, Montserrat González Platas, Lamberto Landete Pascual, Miguel Llaneza-González, María Luisa Martínez Ginés, Jorge Matías-Guiu, José E Meca-Lallana, Mar Mendibe Bilbao, Angel Pérez Sempere, Lucia Romero-Pinel, Albert Saiz, Ester Moral
Publikováno v:
Multiple Sclerosis and Related Disorders
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
r-FISABIO. Repositorio Institucional de Producción Científica
instname
r-ISABIAL. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica y Sanitaria de Alicante
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
Background: The increase in available disease modifying therapies (DMTs) for multiple sclerosis has led to greater emphasis on improving treatment sequencing paradigms. This article summarises the opinions from a panel of 25 experts on treatment swit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e1ec699baafb2aff47971a645a15dd55
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13549
https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13549
Autor:
Susana Sainz de la Maza, Julia Sabin Muñoz, Belén Pilo de la Fuente, Israel Thuissard, Cristina Andreu‑Vázquez, Victoria Galán Sánchez-Seco, Paula Salgado-Cámara, Lucienne Costa-Frossard, Enric Monreal, Lucía Ayuso-Peralta, Lorena García-Vasco, José Manuel García‑Domínguez, María Luisa Martínez-Ginés, Carmen Muñoz Fernández, Judit Díaz-Díaz, Celia Oreja-Guevara, Mayra Gómez‑Moreno, Hugo Martín, Laura Rubio-Flores, María Rosario Blasco, Luisa María Villar-Guimerans, Yolanda Aladro
Publikováno v:
ABACUS. Repositorio de Producción Científica
Universidad Europea (UEM)
Universidad Europea (UEM)
Background: Lymphopenia is a major concern in MS patients treated with dimethyl-fumarate (DMF) as it increases the risk of progressive multifocal leukoencephalopathy. A pronounced reduction in absolute lymphocyte counts (ALCs) early after treatment i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::351d53ee8f221ec535d6ca75c5476ca3
https://hdl.handle.net/11268/11519
https://hdl.handle.net/11268/11519
Publikováno v:
Patient Preference and Adherence. 14:771-779
Purpose Patients with multiple sclerosis (MS) would benefit from continued long-term treatment with disease-modifying therapies, and autoinjectors may help improve patients' satisfaction with therapy, thereby increasing adherence rates. BETACONNECT®